Translink CF acted as the advisor to Institut für histologische und zytologische Diagnostik AG Aarau on the sale of their shares to Affidea Group

Translink Corporate Finance Switzerland  advised Institut für histologische und zytologische Diagnostik AG Aarau on the sale to Affidea Group (Affidea). This acquisition adds two high-quality pathology laboratories – one in Zollikon next to Zürich, close to Affidea’s Centre of Excellence in Breast Cancer, Brust-Zentrum Zurich, and another one in Aarau, Argovia.

With the addition of histopathology, molecular pathology, and cytology diagnostics, Affidea Switzerland now provides a fully integrated and seamless cancer care pathway, covering prevention, early detection, genetic testing, precise diagnosis, personalised treatment, and post-treatment support.

The newly-acquired pathology laboratories are recognised for their outstanding quality standards and rapid biopsy and cytology processing. Biopsy results are delivered within 24 to 48 hours, and urgent cases receive an initial diagnosis on the same day if submitted by noon. Additionally, the laboratories offer next-generation prognostic genomic testing, which allows for personalised breast cancer treatment planning by predicting individual risks of early and late recurrence over a 15-year period.

Comments from Affidea Group

Commenting on the acquisition, Dr Charles Niehaus, Executive Director of Affidea Group, stated, “This acquisition highlights our commitment to increasing patients’ access to fully- integrated oncology pathways. By integrating critical histopathological analysis into our Affidea cancer diagnostics, we ensure that patients receive more personalised diagnosis and prognosis to support effective treatment plans, ultimately improving clinical outcomes. I am delighted to welcome the highly qualified team of Institut für histologische und zytologische Diagnostik AG to the Affidea network and look forward to further building upon our joint expertise.”

Marc-Andre Christinat, Country CEO for Switzerland, added, “With this acquisition, Affidea Switzerland offers a holistic approach to oncology. These services will allow us to enhance our diagnostic capabilities in combination with our existing imaging centres. It will also allow Affidea Switzerland to provide a more end-to-end patient-focused pathway in oncology. I look forward to advancing our vision for integrated cancer care, expanding our capabilities, and delivering high-quality and accessible care across Switzerland.

Comments from Institut für histologische und zytologische Diagnostik AG Aarau

Dr Milo Horcic, Specialist FMH in Pathology, and one of the owners of Institut für histologische und zytologische Diagnostik AG Aarau, stated, “By joining Affidea Group, our goal was to ensure the long-term sustainability of our institute and provide it with the best conditions for continued growth. This transition guarantees the continuity of our mission while creating new opportunities for our clients and our team.”